Trial Profile

Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pazopanib (Primary)
Indications Breast cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions

Most Recent Events

26 Sep 2022 Status changed from active, no longer recruiting to discontinued.
09 Oct 2020 Planned End Date changed from 1 Jun 2019 to 31 Dec 2022.
09 Oct 2020 Planned primary completion date changed from 1 Jun 2019 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com